Clinicopathological Value of p16 Expression in Colorectal Carcinoma
1 other identifier
observational
50
1 country
1
Brief Summary
Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2025
CompletedFirst Submitted
Initial submission to the registry
June 24, 2025
CompletedFirst Posted
Study publicly available on registry
July 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 21, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2026
ExpectedJuly 10, 2025
July 1, 2025
11 months
June 24, 2025
July 7, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluation of p16 Expression in Colorectal Carcinoma.
Immunohistochemical staining of Colorectal tissues by p16 monoclonal antibody
6 months
Secondary Outcomes (1)
Correlation of p16 expression to different clinical and pathological parameters
6 months
Study Arms (1)
Participants
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Interventions
Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Eligibility Criteria
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
You may qualify if:
- Specimens from patients with colorectal cancer.
- Tissue blocks with sufficient material.
- Specimens with sufficient clinical data.
You may not qualify if:
- Tissue blocks with insufficient, destroyed or necrotic material.
- Specimens with insufficient clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Faculty of Medicine
Sohag, Recruiting, Egypt
Biospecimen
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Demonstrator of pathology
Study Record Dates
First Submitted
June 24, 2025
First Posted
July 2, 2025
Study Start
May 1, 2025
Primary Completion
March 21, 2026
Study Completion (Estimated)
December 30, 2026
Last Updated
July 10, 2025
Record last verified: 2025-07